Dalacin T

Pharmacotherapeutic group: anti-acne preparations, anti-infectives for treatment of acne, ATC code: D10AF01 Mechanism of action Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. It binds to the 50S ribosomal subunit and affects ribosome assembly as well as the translational process. Although clindamycin phosphate is inactive *in vitro*, rapid *in vivo* hydrolysis converts the compound to clindamycin, which has antibacterial activity. Clindamycin has demonstrated *in vitro* activity against isolates of the following microorganisms: Anaerobic gram-positive non-spore-forming bacteria, including: *Propionibacterium acnes*. Pharmacodynamic effects Activity correlates with the period of time during which drug levels exceed the minimum inhibitory concentration (MIC) of the pathogen (%T/MIC). Resistance Resistance to clindamycin in *Propionibacterium acnes* may result from mutations at the rRNA antibiotic binding site or from methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit. These alterations may confer cross-resistance to macrolides and streptogramins B (MLSB phenotype). Macrolide-resistant isolates should be tested for inducible clindamycin resistance using the D-test. Cross-resistance between clindamycin and lincomycin has been demonstrated. The prevalence of acquired resistance may vary geographically and over time for selected species, and local resistance data should be consulted, particularly when treating severe infections. Where necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. Especially in severe infections or treatment failure, microbiological diagnosis with confirmation of the pathogen and its susceptibility to clindamycin is recommended. Resistance is usually defined on the basis of susceptibility interpretive criteria (breakpoints) established by regulatory bodies; the CLSI (Clinical and Laboratory Standards Institute) or EUCAST (European Committee on Antimicrobial Susceptibility Testing) for systemically administered antibiotics. These breakpoints may be less relevant for topically administered clindamycin. Although clindamycin is not specifically addressed, EUCAST suggests that, for topical antimicrobial agents, resistance should be defined on the basis of epidemiological cut-off values (ECOFFs) rather than the clinical breakpoints established for systemic administration. However, MIC distributions and ECOFFs for *P. acnes* have not been published by EUCAST. Based on correlations between clinical outcomes in acne patients and the MIC of clindamycin for their *P. acnes* isolates, values of ≤ 256 mg/L are regarded as susceptible for topical clindamycin administration. The CLSI has published MIC ranges for a limited number (58) of unique clinical *P. acnes* isolates collected between 2010 and 2012 in U.S. hospitals. Of these isolates, 91% were susceptible to clindamycin (MIC ≤ 8 mg/L). A recent Belgian surveillance study (2011–2012) of anaerobic bacteria included 22 *P. acnes* isolates, of which 95.5% were susceptible to clindamycin. An earlier European surveillance study including 304 *P. acnes* isolates reported a 15% resistance rate to clindamycin; however, that study used a breakpoint of 0.12 mg/L. Applying the current breakpoint of 4 mg/L, no isolates would have been classified as resistant. Breakpoints CLSI and EUCAST breakpoints for gram-positive anaerobic bacteria are listed below. Although the two bodies report differing values, the resistance breakpoint is the same, since CLSI recognises an intermediate-susceptibility category (4 mg/mL). As noted above, the breakpoints are based on use in systemic infections. EUCAST breakpoints for systemically administered clindamycin Pathogen | Susceptible | Resistant Gram-positive anaerobic bacteria (excluding *Clostridium difficile*) | ≤ 4 mg/L | > 4 mg/L CLSI breakpoints for systemically administered clindamycin Pathogen | Susceptible | Resistant Anaerobes | ≤ 2 mg/L | > 8 mg/L